Shuttle Pharmaceuticals Reports No Revenue, $5.3M Net Loss, and Strategic Merger with United Dogecoin

Shuttle Pharmaceuticals Holdings, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company recorded no revenue for the period, consistent with the previous year. Operating expenses totaled $6.2 million for the first half of 2026, a decrease of 10% from $6.9 million in the same period of 2025. The reduction was primarily driven by an 88% decrease in research and development expenses, which fell to $0.3 million from $2.6 million, largely due to a decrease in subcontractor costs and a reduced employee headcount. General and administrative expenses increased by 7% to $3.1 million, reflecting higher costs associated with investor relations and amortization of developed technology.

The company reported a net loss of $5.3 million for the six months ended June 30, 2026, a 22% improvement compared to a net loss of $6.8 million for the same period in 2025. This improvement was attributed to a significant gain on extinguishment of debt and a favorable change in the fair value of derivative liabilities. The weighted average common shares outstanding increased to approximately 1.0 million from 0.1 million year-over-year, resulting in a net loss per share of $(6.97) for the first half of 2026, compared to $(88.24) in the prior year.

In terms of strategic developments, Shuttle Pharmaceuticals completed a merger with United Dogecoin on May 6, 2026, which resulted in United Dogecoin becoming a wholly-owned subsidiary. This merger is part of the company's strategy to expand into digital asset infrastructure, focusing on blockchain and AI computing. The company also acquired the assets of Molecule.ai in November 2025, enhancing its capabilities in AI-driven drug discovery. The merger and acquisition activities are expected to bolster Shuttle's operational capacity and market presence.

Operationally, the company reported a working capital deficit of approximately $3.1 million as of June 30, 2026, a significant improvement from a deficit of $7.5 million at the end of 2025. Total current assets decreased to $0.4 million, primarily due to cash and cash equivalents of $90,238, down from $334,005 at the end of 2025. Current liabilities also decreased significantly, from $8.0 million to $3.5 million, largely due to the extinguishment of contingent liabilities related to the Molecule.ai acquisition.

Looking ahead, Shuttle Pharmaceuticals is focused on raising additional capital to support its operations and growth initiatives. The company plans to undertake a significant capital raise targeting between $120 million and $150 million, leveraging its existing networks and relationships in the sector. However, the company has expressed concerns regarding its ability to continue as a going concern, emphasizing the need for successful financing to sustain operations and achieve its strategic objectives.